Navigation Links
Plexxikon Inc. to Join Daiichi Sankyo Group
Date:2/28/2011

PARSIPPANY, N.J. and TOKYO, Feb. 28, 2011 /PRNewswire/ -- Daiichi Sankyo Company, Limited (hereinafter Daiichi Sankyo; headquartered in Chuo Ward, Tokyo), today announced that it has concluded an agreement to acquire Plexxikon Inc., a privately held pharmaceutical company based in Berkeley, California with a late-stage oncology product, PLX4032, as well as a promising pipeline and technology platform.

"The acquisition of Plexxikon not only accelerates our entry into the oncology market but strengthens our pipeline and will enable us to achieve our mid- and long-term business objectives of providing world-class, innovative pharmaceuticals in core areas of unmet medical need," said Daiichi Sankyo CEO, Joji Nakayama. "We look forward to working with the esteemed scientists and management team at Plexxikon, who are leaders in the discovery and development of novel small molecule pharmaceuticals to treat human disease."

With the acquisition, Daiichi Sankyo obtains certain co-promotion rights in the United States for PLX4032, which is being jointly developed by Plexxikon and Roche. Interim results from a Phase III trial demonstrated that PLX4032 met co-primary endpoints of overall survival and progression-free survival among patients with previously untreated metastatic melanoma expressing the BRAF mutation.

The acquisition of Plexxikon is consistent with the Daiichi Sankyo commitment to address diverse unmet medical needs, including personalizing medicine to maximize patient benefits. PLX4032 is an elegant example of a targeted therapeutic designed to be administered to patients likely to respond to treatment on the basis of a companion diagnostic test that can detect the presence of a specific genetic mutation.

In addition, the Daiichi Sankyo R&D Division will draw upon the Plexxikon proprietary Scaffold-Based Drug Discovery™ Platform to develop promising new treatments. This unique, systematic, cost-effective platform uses str
'/>"/>

SOURCE Daiichi Sankyo, Co., Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Omeros Announces Expansion of Exclusive License to PDE7 Inhibitors from Daiichi Sankyo
2. Daiichi Sankyo, Inc. Acquires First US-Based Packaging and Manufacturing Facility
3. Reportlinker Adds Daiichi Sankyo Co., Ltd: PharmaVitae Profile
4. Daiichi Sankyo Settled Patent Litigation for Evoxac®
5. Accumetrics, Inc., Daiichi Sankyo, Inc. and Eli Lilly and Company Launch Strategic U.S. Collaboration
6. Daiichi Sankyo/Lilly Respond to ACCF/AHA Clinical Alert on Antiplatelet Therapy
7. Daiichi Sankyo Co, Ltd. Joins the National Cherry Blossom Festival in Washington D.C. as Centennial Celebration Committee Co-Chair
8. Daiichi Sankyo Initiates Largest Single, Double-Blind, Randomized, Phase III Trial for Treatment and Prevention of Recurrent Venous Thromboembolism
9. Daiichi Sankyo Initiates Phase III Trial of Its Investigational Factor Xa Inhibitor, DU-176b, in Patients With Atrial Fibrillation
10. Daiichi Sankyo and Lilly Respond to Speculation on Status of Prasugrel New Drug Application
11. Daiichi Sankyo Announces Clinical Study Data for Oral Factor Xa Inhibitor DU-176b
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)... Inc. (Nasdaq: CRDC ) today announced financial results ... Cardica,s management will hold a conference call at 4:30 ... provide an update on the company,s business. ... 2015, we reintroduced a modified MicroCutter XCHANGE® 30 suitable ... commercial release is focusing primarily on customers in Europe ...
(Date:5/6/2015)... May 6, 2015 Vanda Pharmaceuticals Inc. (Vanda) ... results for the first quarter ended March 31, 2015. ... record quarter for product sales driven by HETLIOZ and ... accessing the 80,000 Non-24 patients in the U.S., the ... patent exclusivity for Fanapt underscores the growth potential of ...
(Date:5/6/2015)... Systems, Inc. (NASDAQ: DCTH ), a specialty pharmaceutical ... emphasis on the treatment of primary and metastatic liver ... March 31, 2015.  Highlights of the ... quarterly product revenue of $0.44 million, an increase of ... 2014; , Activated a prospective patient registry in ...
Breaking Medicine Technology:Cardica Announces Fiscal 2015 Third Quarter Financial Results 2Cardica Announces Fiscal 2015 Third Quarter Financial Results 3Cardica Announces Fiscal 2015 Third Quarter Financial Results 4Cardica Announces Fiscal 2015 Third Quarter Financial Results 5Cardica Announces Fiscal 2015 Third Quarter Financial Results 6Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 2Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 3Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 4Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 5Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 6Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 7Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 8Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 9Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 10Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 11Vanda Pharmaceuticals Reports First Quarter 2015 Financial Results 12Delcath Reports 2015 First Quarter Financial Results 2Delcath Reports 2015 First Quarter Financial Results 3Delcath Reports 2015 First Quarter Financial Results 4Delcath Reports 2015 First Quarter Financial Results 5Delcath Reports 2015 First Quarter Financial Results 6Delcath Reports 2015 First Quarter Financial Results 7Delcath Reports 2015 First Quarter Financial Results 8
... JERSEY CITY, N.J., May 2, 2011 Aoxing ... Pharma"), a specialty pharmaceutical company focusing on research, ... products, announced that its operating subsidiary in China, ... a patent by the State Intellectual Property Office ...
... International, Inc. (NYSE: VRX ) (TSX: VRX) today ... and Cephalon, Inc. (NASADQ: CEPH) on their announcement that Cephalon ... the news, Valeant has withdrawn its consent solicitation. ... Cephalon stockholders and we are pleased that Teva has paid ...
Cached Medicine Technology:Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 2Aoxing Pharmaceutical Company Announces Issuance of Chinese Patent for Naloxone Sublingual Film 3Valeant Pharmaceuticals Congratulates Teva and Cephalon on Their Transaction 2
(Date:5/6/2015)... 06, 2015 As Hilo Medical ... EMR Adoption Model, the hospital looked for new ... and automate processes. The leadership team realized that ... electronic workflows, patient registration still required patients to ... With HIMSS Stage 7 attestation fast approaching, Hilo ...
(Date:5/6/2015)... Experienced Vancouver air conditioning installation and repair ... will now conduct their cooling services, including air conditioning ... commercial and residential units. Strata complex air conditioning services ... technical knowledge as well as a professionally trained staff. ... take away any old air conditioning unit to be ...
(Date:5/6/2015)... Vancouver, BC (PRWEB) May 06, 2015 ... colon hydrotherapy supplier, is excited to announce a ... will help reduce the industry’s carbon footprint while ... These kits feature Eco-Flex™, the world’s ... “This is a game-changer for hydrotherapists,” claims the ...
(Date:5/6/2015)... Animals make just as good friends as they do ... health. An Ohio veterinarian has been observing this ... health advantages of owning a pet. , “When animals and ... ownership, there are proven health benefits for people-- including physical, ... the Animal Medical Center of Streetsboro said. Every ...
(Date:5/6/2015)... Inversion Studios, a full-service training ... Pilates classes, provides personalized individual instruction and now ... its new Pilates Ring magic circle. , Inversion ... stronger, more centered and graceful, Inversion Studios and ... to healthy fitness through yoga and Pilates. With ...
Breaking Medicine News(10 mins):Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 2Health News:Access Electronic Patient Signatures Help Hilo Meet HIMSS Stage 7 Paperless Targets & Save $200,000 a Year on Consent Forms 3Health News:Pro Ace Care Now Does Air Conditioning Installation for Strata Complexes 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 2Health News:World’s First Compact Colon Hydrotherapy Speculum Kit 3Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 2Health News:Veterinarian Supports 2015 HABRI Study Citing Increase in Health Advantages of Pet Owners 3Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 2Health News:Inversion Studios’ New Pilates Ring Is Circle of Magic for Body, Mind and Spirit 3
... than that, after a lumpectomy for breast cancer. Researchers from ... ubiquitous tummy fat , can in fact be used to ... two birds with one stone, a flatter belly and a ... a 'supercharged' fat mixture into the breast tissue after it ...
... a genetic marker that increases a person's risk of colon ... 10-year study was conducted by a team of researchers from ... Public Health, the Catalan Institute of Oncology in Spain, the ... Israel Institute of Technology, including Stephen Gruber and Gad Rennert. ...
... announced today that ALIGN(R) is now available through ... builds and maintains a natural defense against ... as constipation, diarrhea, abdominal discomfort, urgency, gas and ... contains Bifantis(R) (Bifidobacterium infantis 35624), a natural probiotic ...
... western media, the government of the Peoples Republic of China ... the countrys Food and Drug Administration. ,,He was ... of dereliction of duty at a trial in May. ... led to several deaths. , ,China has been ...
... Microsoft, aware that a large number of Internet searches ... presence in the healthcare sector . This, claims Cambridge ... healthcare professionals and medical device manufacturers. According to a ... are already having to come to terms with informed ...
... to detect a disease in its very early ... slowly gaining greater acceptance across Europe . Furthermore, ... and invasive procedures, in addition to reducing bed ... Europe, age-related diseases such as cancer, Alzheimer's disease, ...
Cached Medicine News:Health News:Stem Cells In Belly Fat To Enhance Or Reconstruct Breasts 2Health News:Food Safety Chief Executed for Bribery in China 2Health News:Food Safety Chief Executed for Bribery in China 3Health News:Food Safety Chief Executed for Bribery in China 4Health News:Battle Between Google and Microsoft Could Trigger Revolution in Healthcare 2Health News:Pharmacogenomic Market Gaining Greater Acceptance Across Europe 2Health News:Pharmacogenomic Market Gaining Greater Acceptance Across Europe 3
QC 900 is an assayed quality control material for analyzers measuring hematocrit by electrical conductivity methodologies. It is available in two (2) levels for monitoring analyzer performance at var...
... 823 is an assayed quality ... the performance of blood gas, ... instrumentation. It is available in ... analyzer performance at varying points ...
... QC 463 is a quality control ... monitoring the performance of blood gas, electrolyte, ... practical alternative to the use of human ... in three (3) levels for monitoring analyzer ...
... and probe system used together to quantify ... based system is a sandwich nucleic acid ... for RNA detection and quantification, by amplifying ... technology. Branched DNA allows immediate quantification of ...
Medicine Products: